

Supplementary information for the article:

Stojanović, M.; Lukić, I.; Marinković, E.; Kovačević, A.; Miljković, R.; Tobias, J.; Schabussova, I.; Zlatović, M.; Barisani-Asenbauer, T.; Wiedermann, U.; Inić-Kanada, A. Cross-Reactive Effects of Vaccines: Heterologous Immunity between Tetanus and Chlamydia. *Vaccines* **2020**, *8* (4), 719.
<https://doi.org/10.3390/vaccines8040719>.



Supplementary Data : Table S1

Characteristics of selected anti-tetanus mAbs [35,36].

mAb26	mAb51
1. Affinity constant and rate of establishment the anti-TeNT mAb/TeNT interaction	
$K_a = 0.4 \pm 0.2 \times 10^8 \text{ M}^{-1}$	$K_a = 2.4 \pm 0.4 \times 10^8 \text{ M}^{-1}$
$k_{on} = 1.1 \pm 0.2 \times 10^3 \text{ M}^{-1} \text{ s}^{-1}$	$k_{on} = 185 \pm 16 \times 10^3 \text{ M}^{-1} \text{ s}^{-1}$
Low affinity mAb	High affinity mAb
2. Epitope positions on TeNT	
Epitopes for mAb26 and mAb51 are located on close proximity of the ganglioside-binding place	
3. Capability to inhibit TeNT/GD1b interactions	
Limited inhibition of TeNT/GD1b interactions	Complete inhibition of TtNT/GD1b interactions
(29.9 ± 3.1 %)	(98.8 ± 1.1 %)
4. <i>In vivo</i> protective potential against TeNT intoxication	
Not protective against TeNT intoxication	Fully protective against TeNT intoxication